Please assess the completion status of the following clinical trial:

Trial Title: Therapy of Metastatic Breast Cancer With Paclitaxel and Liposomal Doxorubicin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women \>/= 18 years with histologically proven metastatic breast cancer~* No prior chemotherapy in the advanced situation~* ECOG \</= 2~* Adequate bone marrow reserve~* left ventricular ejection fraction (LVEF) \>/= 50, measured within 4 weeks before study treatment~* Existence of written informed consent~Exclusion Criteria:~* Previous high dose therapy with stem cell support~* Prior adjuvant treatment with cumulative anthracycline dose of 600 mg/m² Epirubicin, 300 mg/m² Doxorubicin, 80 mg/m² Mitoxantrone~* Concomitant hormon- or chemotherapy or radiation therapy~* Her2/neu overexpression~* pregnancy or breast feeding

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Myocet/Paclitaxel (Type: EXPERIMENTAL): 20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d

Based on this trial design, predict the completion outcome and termination type (if applicable).